280
Views
0
CrossRef citations to date
0
Altmetric
Original Article

Imaging features of hepatobiliary MRI and the risk of hepatocellular carcinoma development

, , , , , , , , , , , & show all
Pages 1470-1477 | Received 22 Feb 2022, Accepted 19 Jun 2022, Published online: 04 Jul 2022

References

  • Kim BH, Park JW. Epidemiology of liver cancer in South Korea. Clin Mol Hepatol. 2018;24(1):1–9.
  • McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(Suppl. 1):4–13.
  • Kim KM, Kim J, Sinn DH, et al. Treatment for occult hepatocellular carcinoma: does it offer survival advantages over symptom-driven treatment? Scand J Gastroenterol. 2018;53(6):727–733.
  • European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
  • Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750.
  • Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317–370.
  • Braillon A. Hepatocellular carcinoma. Lancet. 2012;380(9840):469.
  • Lederle FA, Pocha C. Screening for liver cancer: the rush to judgment. Ann Intern Med. 2012;156(5):387–389.
  • Park HJ, Kim SY. Imaging modalities for hepatocellular carcinoma surveillance: expanding horizons beyond ultrasound. J Liver Cancer. 2020;20(2):99–105.
  • Kim DH, Hong SB, Choi SH, et al. Surveillance failure in ultrasound for hepatocellular carcinoma: a systematic review and meta-analysis. Gut. 2022;71(1):212–213.
  • Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154(6):1706–1718.e1.
  • Park SH, Kim B. Liver magnetic resonance imaging for hepatocellular carcinoma surveillance. J Liver Cancer. 2020;20(1):25–31.
  • Kim SY, An J, Lim YS, et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncol. 2017;3(4):456–463.
  • Korean Liver Cancer Association, National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the management of hepatocellular carcinoma. Korean J Radiol. 2019;20(7):1042–1113.
  • Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–174.
  • Tanabe M, Kanki A, Wolfson T, et al. Imaging outcomes of liver imaging reporting and data system version 2014 category 2, 3, and 4 observations detected at CT and MR imaging. Radiology. 2016;281(1):129–139.
  • Tang A, Bashir MR, Corwin MT, et al. Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review. Radiology. 2018;286(1):29–48.
  • Agnello F, Albano D, Sparacia G, et al. Outcome of LR-3 and LR-4 observations without arterial phase hyperenhancement at Gd-EOB-DTPA-enhanced MRI follow-up. Clin Imaging. 2020;68:169–174.
  • Kim TK, Lee E, Jang HJ. Imaging findings of mimickers of hepatocellular carcinoma. Clin Mol Hepatol. 2015;21(4):326–343.
  • Kim YK, Moon WS, Cho BH, et al. MRI findings of focal eosinophilic liver diseases. AJR Am J Roentgenol. 2005;184(5):1541–1548.
  • Tang A, Singal AG, Mitchell DG, et al. Introduction to the liver imaging reporting and data system for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2019;17(7):1228–1238.
  • van der Pol CB, Lim CS, Sirlin CB, et al. Accuracy of the liver imaging reporting and data system in computed tomography and magnetic resonance image analysis of hepatocellular carcinoma or overall malignancy—a systematic review. Gastroenterology. 2019;156(4):976–986.
  • Onyirioha K, Joshi S, Burkholder D, et al. Clinical outcomes of patients with suspicious (LI-RADS 4) liver observations. Clin Gastroenterol Hepatol. 2022.
  • Arvind A, Joshi S, Zaki T, et al. Risk of hepatocellular carcinoma in patients with indeterminate (LI-RADS 3) liver observations. Clin Gastroenterol Hepatol. 2021.
  • International Working Party. Terminology of nodular hepatocellular lesions. Hepatology. 1995;22:983–993.
  • Peng C, Kascakova S, Chiappini F, et al. Discrimination of cirrhotic nodules, dysplastic lesions and hepatocellular carcinoma by their vibrational signature. J Transl Med. 2016;14:9.
  • Inchingolo R, Faletti R, Grazioli L, et al. MR with Gd-EOB-DTPA in assessment of liver nodules in cirrhotic patients. World J Hepatol. 2018;10(7):462–473.
  • Kobayashi M, Ikeda K, Hosaka T, et al. Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer. 2006;106(3):636–647.
  • Sato T, Kondo F, Ebara M, et al. Natural history of large regenerative nodules and dysplastic nodules in liver cirrhosis: 28-year follow-up study. Hepatol Int. 2015;9(2):330–336.
  • Korean Liver Cancer Association, National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the management of hepatocellular carcinoma. Gut Liver. 2019;13(3):227–299.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.